WealthPlan Investment Management LLC Makes New $344,000 Investment in Gilead Sciences, Inc. $GILD

WealthPlan Investment Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 3,106 shares of the biopharmaceutical company’s stock, valued at approximately $344,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. New York State Teachers Retirement System lifted its position in Gilead Sciences by 1.8% in the second quarter. New York State Teachers Retirement System now owns 1,123,885 shares of the biopharmaceutical company’s stock valued at $124,605,000 after purchasing an additional 19,842 shares during the last quarter. Rosenberg Matthew Hamilton lifted its position in Gilead Sciences by 13.7% in the second quarter. Rosenberg Matthew Hamilton now owns 2,522 shares of the biopharmaceutical company’s stock valued at $280,000 after purchasing an additional 304 shares during the last quarter. Mutual Advisors LLC lifted its position in Gilead Sciences by 16.9% in the second quarter. Mutual Advisors LLC now owns 21,228 shares of the biopharmaceutical company’s stock valued at $2,467,000 after purchasing an additional 3,072 shares during the last quarter. Ritholtz Wealth Management lifted its position in Gilead Sciences by 12.4% in the second quarter. Ritholtz Wealth Management now owns 115,166 shares of the biopharmaceutical company’s stock valued at $12,768,000 after purchasing an additional 12,726 shares during the last quarter. Finally, Sagespring Wealth Partners LLC lifted its position in Gilead Sciences by 28.5% in the second quarter. Sagespring Wealth Partners LLC now owns 17,351 shares of the biopharmaceutical company’s stock valued at $1,924,000 after purchasing an additional 3,848 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the transaction, the chief executive officer owned 595,725 shares in the company, valued at approximately $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,500 shares of company stock worth $8,281,540. 0.27% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have weighed in on GILD shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Citigroup boosted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Finally, Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $118.65.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $122.81 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market cap of $152.38 billion, a PE ratio of 24.46, a P/E/G ratio of 0.81 and a beta of 0.34. The business has a 50 day moving average of $115.22 and a 200 day moving average of $110.53. Gilead Sciences, Inc. has a 52 week low of $85.60 and a 52 week high of $124.11.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.